无创正压通气治疗在COPD急性发作患者中的应用研究  

The Application of NIPPV in the Treatment of COPD Patients with Acute Attack

作　　者：孙锎[1] 罗萍[1] 

机构地区：[1]重庆三峡中心医院呼吸内科,重庆404000

出　　处：《中外医疗》2013年第1期3-3,5,共2页China & Foreign Medical Treatment

摘　　要：目的研究无创正压通气治疗在慢性阻塞性肺病(COPD)急性发作患者治疗中的应用价值。方法回顾性分析2009年6月—2012年6月该院采用无创正压通气联合药物治疗的86例COPD急性发作患者的临床资料,并以同期单纯采用药物治疗的86例患者为对照组,比较两组患者治疗效果。结果治疗7d后,观察组患者血浆乳酸为(2.52±0.44)mmol/L、C反应蛋白水平为(11.29±2.23)mg/L,对照组分别为(3.11±0.53)mmol/L、(18.75±2.92)mg/L,组间比较差异具有统计学意义(P<0.05)。观察组患者住院治疗时间为(8.25±3.17)d、平均治疗费用为(2457.29±553.14)元,对照组患者住院治疗时间为(12.27±4.52)d、平均治疗费用为(2954.57±613.37)元,组间比较差异有统计学意义(P<0.05)。结论在常规药物治疗的基础上联合应用无创正压通气治疗,可有效提高疗效,缩短病程,值得临床研究应用。Objective To study the application value of NIPPV in the treatment of COPD patients with acute attack. Methods Ret- rospective analysis from June 2009 to June 2012 by NIPPV our joint drug therapy of 86 patients with COPD patients with acute attack of the clinical data, and the same period with only with drug therapy of 86 patients as control group, compared with two groups of patients therapeutic effect. Results Treatment for 7 d, watch the groups of patients for plasma lactic acid （2.52±0.44） mmol/L, c-reactive protein level （11.29±2.23）mg/L, and the control group were （3.11±0.53） mmol/L, （18.75±2.92）mg/L, comparative differences between groups are statistically significant （P〈0.05）. The observation group patients hospitalized for time （8.25 ± 3.17）d, average treatment costs for （2457.29_＋553.14）yuan, patients hospitalized for time （12.27±4.52）d, average treatment costs for （2954.57±613.37）yuan, comparative differences between groups are statistically significant （P〈0.05）. Conclusions On the basis of routine therapy combined application NIPPV treatment, which can effectively enhance the curative effect, shorten the duration of symptoms, and clinical research applications.

关 键 词：COPD 急性发作 无创正压通气 应用研究 

分 类 号：R4[医药卫生—临床医学]